Molecular docking-guided design, synthesis, and biological evaluation of novel multitarget HDAC/ROCK inhibitors

Authors: Beljkas, Milan; Zukic, Selma; Mirjacic Martinovic, Katarina; Djuric, Ana; Vuletic, Ana; Jallet, Corinne; Holzel, Julia; Bottger, Elias; Gajic, Mihajlo; Zivanovic, Marija; Santibanez, Juan F; Stark, Holger; Zivkovic, Aleksandra; Srdic-Rajic, Tatjana; Arimondo, Paola; Maran, Uko; Nikolic, Katarina; Petkovic, Milos; Oljacic, Slavica

Source journal: RSC medicinal chemistry (2026-11-03)

DOI: 10.1039/d6md00613b

Abstract

Histone deacetylases (HDACs) and Rho-associated coiled-coil containing protein kinases (ROCKs) play key roles in tumor progression, metastasis, and immunomodulation, particularly in aggressive malignancies such as triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC). Previous in silico and in vitro studies demonstrated the therapeutic promise of dual HDAC/ROCK inhibition and led to the identification of C-9 as the first-in-class multitarget HDAC/ROCK inhibitor and the lead compound of this study. Using a structure-based drug design (SBDD) approach, a novel series of multitarget HDAC/ROCK inhibitors was developed and synthesized. Among them, compounds C-35 and C-40 exhibited pronounced cytotoxicity, surpassing the reference selective HDAC6 and ROCK inhibitors tubastatin A and fasudil. Both compounds induced early apoptosis, caused cell-cycle arrest, and reduced PD-L1 expression. Furthermore, C-35 and C-40 demonstrated significant anti-migratory and anti-invasive effects in TNBC cell lines. Microsomal stability studies revealed sex-dependent metabolic differences for C-40, which showed lower stability and approximately fourfold higher in vitro clearance in female compared to male microsomes. In contrast, C-35 exhibited favorable microsomal stability in both male and female human liver microsomes, with only a modest 1.2-fold faster metabolism in females. Overall, this study highlights the therapeutic potential of multitarget HDAC/ROCK inhibition and establishes a robust computational-experimental approach for future inhibitor development.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.